Key Takeaways
- • Integer Holdings (NYSE: ITGR) shareholders overwhelmingly approved a $5.7 billion acquisition by an affiliate of KKR-managed investment funds, with 26,065,335 votes for, 10,513 against, and 1,993 abstaining, according to a Form 8-K filed with the SEC.
- • The deal was first announced in August 2026, and Integer officials expect closing by the end of 2026, subject to customary conditions and required regulatory approvals.
- • Integer, a Plano, Texas-based company, is one of the world's largest medical device contract development and manufacturing organizations (CDMOs), serving cardiovascular, neuromodulation, and cardiac rhythm management markets.
- • Management says that operating as a privately held KKR portfolio company will give Integer additional flexibility and long-term capital.
- • The transaction reflects growing private equity interest in medtech, following Hologic's $18.3 billion go-private deal earlier in 2026 and GTCR's sale of the Biosurgery unit of Corza Medical.
Summary
IntEger (NYSE: ITGR) shareholders have overwhelmingly approved a $5.7 billion acquisition of the company by an affiliate of KKR-managed investment funds, according to a Form 8-K filed with the U.S. Securities and Exchange Commission. The vote tally was 26,065,335 in favor, 10,513 against, and 1,993 abstaining. The proposed transaction was first announced in August 2026.
Plano, Texas-based Integer is one of the world's largest medical device contract development and manufacturing organizations, serving the cardiovascular, neuromodulation, and cardiac rhythm management markets. Company officials expect the acquisition to close by the end of 2026, subject to customary closing conditions and required regulatory approvals. They have said that becoming a privately held KKR portfolio company will give Integer additional flexibility and access to long-term capital.
The deal fits a broader pattern of private equity activity in healthcare technology. Private equity has long been active in medical device contract manufacturing and has increasingly turned its attention to medtech original equipment manufacturers, according to the report by Medical Design & Outsourcing. Over the summer, GTCR agreed to sell the Biosurgery unit of its Corza Medical business, and Resmed agreed to sell its MatrixCare software business to a private equity buyer. Hologic's $18.3 billion go-private transaction earlier in 2026 was described as the most significant private equity move in the sector recently.
Medical Design & Outsourcing executive editor Chris Newmarker reported the story.
Plano, Texas-based Integer is one of the world's largest medical device contract development and manufacturing organizations, serving the cardiovascular, neuromodulation, and cardiac rhythm management markets. Company officials expect the acquisition to close by the end of 2026, subject to customary closing conditions and required regulatory approvals. They have said that becoming a privately held KKR portfolio company will give Integer additional flexibility and access to long-term capital.
The deal fits a broader pattern of private equity activity in healthcare technology. Private equity has long been active in medical device contract manufacturing and has increasingly turned its attention to medtech original equipment manufacturers, according to the report by Medical Design & Outsourcing. Over the summer, GTCR agreed to sell the Biosurgery unit of its Corza Medical business, and Resmed agreed to sell its MatrixCare software business to a private equity buyer. Hologic's $18.3 billion go-private transaction earlier in 2026 was described as the most significant private equity move in the sector recently.
Medical Design & Outsourcing executive editor Chris Newmarker reported the story.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.